|
| 36720081 | Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). | | 2023 |
| 37582396 | Using advanced analytics to help identify women who are more likely to have a severe subjective experience of vulvovaginal atrophy: a modeling study. | | 2023 |
| 37278023 | Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts' perspective. | | 2023 |
| 37084589 | Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice. | | 2023 |
| 36651193 | Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review. | Hum Reprod Update | 2023 |
| 37199295 | Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause. | | 2023 |
| 34952794 | Alternative and non-hormonal treatments to symptoms of menopause. | | 2022 |
| 35703057 | British Menopause Society Tool for clinicians: Testosterone replacement in menopause. | Post Reproductive Health | 2022 |
| 35443829 | Consensus-led recommendations supporting choice and personalisation of Hormone replacement therapy in menopause care. | Post Reproductive Health | 2022 |
| 35688490 | Impact of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol on cardiovascular markers in women diagnosed with premature ovarian insufficiency or an early menopause: a randomised pilot trial. | | 2022 |
| 35486948 | The effect of micronized progesterone and medroxyprogesterone acetate in combination with transdermal estradiol on hemostatic biomarkers in postmenopausal women diagnosed with POI and early menopause: a randomized trial. | Menopause | 2022 |
| 35249262 | Reflections on a specialist HIV menopause service: Experiences of managing menopause in women living with HIV: Experiences of managing menopause in women living with HIV. | HIV Medicine | 2022 |
| 34597899 | A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. | Psychoneuroendocrinology | 2021 |
| 34175471 | Real-World Practices and Attitudes Towards Intimate Self- Care: Results From An International Women's Survey. | Journal of Gynecology Obstetrics and Human Reproduction | 2021 |
| 34169795 | Cardiometabolic health in premature ovarian insufficiency. | Climacteric | 2021 |
| 33459135 | BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020. | Post Reprod Health | 2021 |
| 33451805 | Premature ovarian insufficiency: A toolkit for the primary care physician. | | 2021 |
| 34192961 | A cross-sectional national questionnaire survey assessing the views of members of the British Menopause Society on the management of patients with unscheduled bleeding on hormone replacement therapy. | Post Reproductive Health | 2021 |
| 33973541 | A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative. | Menopause | 2021 |
| 33495787 | Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. | European Heart Journal | 2021 |
| 32990054 | Vaginal lubricants and moisturizers: a review into use, efficacy, and safety. | Climacteric | 2021 |
| 32856973 | The European Vulvovaginal Epidemiological Survey (EVES). Impact of history of breast cancer on prevalence, symptoms, sexual function and quality of life related to vulvovaginal atrophy. | Gynecological Endocrinology | 2021 |
| 33434082 | Premature ovarian insufficiency: a toolkit for the primary care physician. | Climacteric | 2021 |
| 34498504 | Progress in understanding and management of premature ovarian insufficiency. | Climacteric | 2021 |
| 34823999 | Diagnosis and management of premature ovarian insufficiency. | | 2021 |
| 33158486 | No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA). | | 2020 |
| 32019391 | Purified and specific cytoplasmic pollen extract: a non-hormonal alternative for the treatment of menopausal symptoms. | Gynecological Endocrinology | 2020 |
| 32068686 | The European Vulvovaginal Epidemiological Survey (EVES): impact on sexual function of vulvovaginal atrophy of menopause. | Menopause | 2020 |
| 32160277 | Response to Letter to the Editor: "Global Consensus Position Statement on the Use of Testosterone Therapy for Women". | J Clin Endocrinol Metab | 2020 |
| 33045914 | The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. | Post Reproductive Health | 2020 |
| 33045913 | A direct comparison of women's perceptions and acceptability of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol in the management of young postmenopausal women, under 45 years of age. | Post Reproductive Health | 2020 |
| 33038141 | Does age at the start of treatment for vaginal atrophy predict response to vaginal estrogen therapy? Post hoc analysis of data from a randomized clinical trial involving 205 women treated with 10⿿μg estradiol vaginal tablets. | Menopause | 2020 |
| 32627698 | Symptoms, attitudes and treatment perceptions of vulvo-vaginal atrophy in UK postmenopausal women: Results from the REVIVE-EU study. | Post Reproductive Health | 2020 |
| 32896176 | Premature ovarian insufficiency: an International Menopause Society White Paper. | Climacteric | 2020 |
| 31097180 | Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. | | 2019 |
| 30422932 | The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey. | Menopause | 2019 |
| 30280667 | Cardiovascular Risk in Perimenopausal Women. | Current Vascular Pharmacology | 2019 |
| 30819073 | Premature Ovarian Insufficiency and Long-Term Health Consequences. | Current Vascular Pharmacology | 2019 |
| 31488288 | Global Consensus Position Statement on the Use of Testosterone Therapy for Women. | J Sex Med | 2019 |
| 31474158 | Global Consensus Position Statement on the Use of Testosterone Therapy for Women. | Climacteric | 2019 |
| 31484631 | Global Consensus Position Statement on the use of Testosterone Therapy for Women. | Maturitas | 2019 |
| 31411904 | Vulvovaginal atrophy in women after cancer. | Climacteric | 2019 |
| 31498871 | Global Consensus Position Statement on the Use of Testosterone Therapy for Women. | J Clin Endocrinol Metab | 2019 |
| 31192760 | BMS - Consensus statement: Bioidentical HRT. | Post Reproductive Health | 2019 |
| 29553288 | The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. | Climacteric | 2018 |
| 29533369 | Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action. | Menopause | 2018 |
| 27916205 | Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. | Fertility and Sterility | 2017 |
| 28385352 | Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. | Lancet, The | 2017 |
| 27631561 | Climacteric: past, present and future! | Climacteric | 2016 |
| 27148764 | Menopause in the 21st century: the need for research and development. | Climacteric | 2016 |